Infectious diseases have long been a major concern for global health. While much attention is given to bacterial and viral infections, fungal diseases remain an underappreciated and growing threat. With limited treatment options and rising resistance to existing antifungal drugs, the world is facing a silent crisis that could have devastating consequences. David Angulo, MD, an infectious disease specialist and the president and CEO of SCYNEXIS, sheds light on the urgent need for new antifungal treatments and the challenges in combating fungal resistance in this interview with Infection Control Today® (ICT®).

Understanding the Scope of Fungal Infections

In this interview, Angulo explains that when most people think of fungal infections, they often imagine superficial conditions like toenail or yeast infections. While these are common and generally treatable, a far more dangerous category of fungal diseases exists—one that attacks the lungs, bloodstream, brain, and other vital organs. These invasive fungal infections are often life-threatening, with mortality rates ranging from 20% to 80%, particularly among immunocompromised individuals.

Angulo explains that patients undergoing chemotherapy, organ transplant recipients, and those in intensive care units are at the highest risk. In these situations, “You have multiple catheters placed in your body because of that reason, and then the fungi had the opportunity to get into your body and to cause these very severe infections,” Angulo said.

Angulo discusses the most common invasive fungal infections, which include:

Angulo emphasizes the critical need for innovation: “Over the years, fungi have developed resistance against many of them, and at this point, that’s really the biggest concern,” he said

His company, SCYNEXIS, is at the forefront of this fight, developing a new class of antifungal drugs called triterpenoids. “Our focus has been in trying to address the problem of antimicrobial resistance in the antifungal space, and really how to tackle those very difficult to treat diseases. That has been really the focus and the passion of this organization for the past 10 years,” he explains.
As Angulo told ICT, “The antibacterial space was developed much earlier and faster, but right now, with a better understanding of the impact of fungal diseases and the development of resistance of fungal pathogens that has been evolving in the US, the CDC runs the primary surveillance program regarding the development of antimicrobial and antifungal resistance.”

By raising awareness and pushing for policy changes, the fight against deadly fungal infections remains a global priority.

Listen to ICT’s interview with Angulo to learn more about the history and treatment of fungal diseases.